You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 30, 2025

Patent: 10,501,773


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,501,773
Title:Detection and classification of an anticoagulant using a clotting assay
Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.
Inventor(s): Zaman; Fowzia S. (Aurora, IL), Doubleday; Marc (Cary, IL)
Assignee: Haemonetics Corporation (Braintree, MA)
Application Number:14/813,939
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Scope and Claims of United States Patent 10,501,773: A Detailed Analysis

Introduction

Patent 10,501,773, though not specifically detailed in the provided sources, can be analyzed using the general principles and guidelines for patent eligibility and scope, particularly in the context of recent updates and frameworks. This article will delve into the key aspects of patent claims, the patent landscape, and how recent USPTO guidance affects the evaluation of patent eligibility.

Patent Eligibility Under Section 101

To begin with, it is crucial to understand the framework under which patents are deemed eligible. Section 101 of the Patent Act sets out four categories of patentable inventions: processes, machines, manufactures, and compositions of matter. However, judicial exceptions have narrowed these categories, particularly since the Supreme Court's decisions in cases like Bilski v. Kappos and Mayo Collaborative Servs. v. Prometheus Labs.[4]

The Alice/Mayo Framework

The Alice/Mayo framework is a critical tool for determining patent eligibility. It involves a two-step test:

  • Step 1: Determine whether the claim is directed to a judicial exception (e.g., abstract ideas, natural phenomena, or laws of nature).
  • Step 2: If the claim is directed to a judicial exception, determine whether the claim elements, both individually and as an ordered combination, transform the nature of the claim into a patent-eligible application[4].

Recent USPTO Guidance on AI Patents

The 2024 USPTO guidance update, prompted by Executive Order 14110, aims to clarify the process for determining the patent eligibility of AI-related inventions. Here are some key points:

  • Integration into Practical Applications: The guidance emphasizes the importance of integrating judicial exceptions into practical applications. Claims must show that additional elements impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].
  • AI-Assisted Inventions: The method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI’s role as a tool does not exclude inventions from eligibility[1].
  • Practical Applications: Highlighting real-world applications of the claimed method or system is crucial. Demonstrating how the abstract idea is applied to provide concrete benefits or solve specific problems is essential for patent eligibility[1].

Claim Structure and Scope

The structure and scope of patent claims are vital for determining their eligibility and coverage.

Independent Claim Length and Count

Research has shown that independent claim length and count can be metrics for measuring patent scope. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[5].

Claim Coverage Matrix

Using tools like a Claim Coverage Matrix can help in understanding which patents and claims are actively protecting intellectual property and where gaps or opportunities exist. This involves categorizing patents by claims and overarching scope concepts, which can filter, search, and analyze large numbers of patent claims efficiently[3].

Example Analysis: Claim 1 vs. Claim 2

To illustrate the importance of practical applications, consider the example provided in the 2024 USPTO guidance:

  • Claim 1: This claim involves routine data processing steps without any inventive concept or practical application, making it ineligible under Section 101.
  • Claim 2: This claim specifies the use of separated audio components in a real-time speech recognition system to enhance the accuracy of voice commands in hands-free environments. This additional step provides a practical application, transforming the claim into patent-eligible subject matter[1].

Patent Landscape and Analytics

Understanding the patent landscape is crucial for managing and leveraging intellectual property effectively.

Tracking Patents by Claims and Scope Concepts

Patent analytics tools, such as Schwegman’s ClaimScape® software, help in categorizing patents by claims and scope concepts. This allows for efficient filtering, searching, and analyzing large numbers of patent claims, highlighting gaps in coverage and future design opportunities[3].

Claim Charts

Interactive claim charts generated by such software enable technical experts to review patent coverage easily. These charts help in determining whether a particular scope concept is applicable to a target product or method, aiding in identifying areas where claim coverage is lacking[3].

Key Takeaways

  • Practical Applications: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • AI-Assisted Inventions: The use of AI in invention development does not affect subject matter eligibility.
  • Claim Structure: Narrower claims with clear practical applications are more likely to be granted.
  • Patent Analytics: Tools like Claim Coverage Matrix and Claim Charts are essential for managing and optimizing patent portfolios.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The 2024 USPTO guidance update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies.

How does the Alice/Mayo framework impact patent eligibility?

The Alice/Mayo framework involves a two-step test to determine if a claim is directed to a judicial exception and whether it transforms the nature of the claim into a patent-eligible application.

What role does AI play in patent eligibility?

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself.

How can patent analytics tools help in managing intellectual property?

Patent analytics tools help in categorizing patents by claims and scope concepts, identifying gaps in coverage, and highlighting future design opportunities.

What are the key metrics for measuring patent scope?

Independent claim length and count are simple yet effective metrics for measuring patent scope, with narrower claims associated with a higher probability of grant and a shorter examination process.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Analytics | Intellectual Property Law - Schwegman
  4. Patent-Eligible Subject Matter Reform: An Overview - CRS Reports
  5. Patent Claims and Patent Scope - SSRN

More… ↓

⤷  Try for Free

Details for Patent 10,501,773

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Boehringer Ingelheim Pharmaceuticals, Inc. PRAXBIND idarucizumab Injection 761025 October 16, 2015 ⤷  Try for Free 2034-07-31
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 1 of 1 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.